Medclair AB (NGM:MCLR) Accounts Receivable: kr4.70 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:MCLR Medclair AB NGM:MCLR
71 GF Score
Price kr2.90
GF Value kr2.39
Valuation Modestly Overvalued
View Full Analysis

What is Medclair AB Accounts Receivable?

Medclair AB NGM:MCLR 71 Accounts Receivable is kr4.70 Mil as of Mar. 2026. GuruFocus rates NGM:MCLR with a GF Score™ of 71/100 and a GF Value™ of kr2.39 (Modestly Overvalued).

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Medclair AB's accounts receivables for the quarter that ended in Mar. 2026 was kr4.70 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Medclair AB's Days Sales Outstanding for the quarter that ended in Mar. 2026 was 23.53.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Medclair AB's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was kr0.19.


Medclair AB Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Medclair AB's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=4.703/18.238*91
=23.53

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Medclair AB's accounts receivable are only considered to be worth 75% of book value:

Medclair AB's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(20.372+0.75 * 4.703+0.5 * 6.825-10.319
-0-0)/91.647
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Medclair AB Accounts Receivable Related Terms


Medclair AB Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Medclair AB's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medclair AB Accounts Receivable Chart

Medclair AB Annual Data
Trend Apr16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.59 2.90 5.12 3.76 4.12

Medclair AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.53 5.05 3.63 4.12 4.70
NGM:MCLR
71GF Score
Medclair AB NGM:MCLR
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medclair AB Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of kr4.70 Mil mean?
Medclair AB (NGM:MCLR) has a Accounts Receivable of kr4.70 Mil as of Mar. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Medclair AB and its competitors.
Is Medclair AB's Accounts Receivable too high?
Medclair AB's current Accounts Receivable is kr4.70 Mil. Overall, Medclair AB has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's Accounts Receivable compare to ABT and SYK?
Medclair AB's Accounts Receivable of kr4.70 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Devices & Instruments company?
A good Accounts Receivable depends on the Medical Devices & Instruments industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Medclair AB and its competitors. Medclair AB's current Accounts Receivable is kr4.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.39, compared to a current price of kr2.90 — trading 21.3% above its estimated fair value. The current Accounts Receivable is kr4.70 Mil. Medclair AB's overall GF Score™ is 71/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current Accounts Receivable is kr4.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medclair AB (NGM:MCLR) Overvalued in 2026?

Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued. The current stock price of kr2.90 is trading 21.3% above its estimated GF Value™ of kr2.39. GuruFocus considers Medclair AB to be Modestly Overvalued.

Key valuation signals for NGM:MCLR:

  • Accounts Receivable: kr4.70 Mil
  • GF Value™: kr2.39 vs. price of kr2.90 (21.3% above fair value)
  • GF Score™: 71/100

No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medclair AB Business Description

Address Fraktflygargatan 1, Stockholm, SWE, 128 30
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
71GF Score

Get the complete analysis for NGM:MCLR

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.90
Price
kr2.39
GF Value